{"gene":"TACSTD2","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1995,"finding":"TACSTD2/EGP-1 is phosphorylated in vivo on serine 303 in its cytoplasmic domain by protein kinase C (PKC); metabolic 32P-labeling and immunoprecipitation confirmed phosphorylation on serine, in vitro kinase assays identified PKC (not PKA) as the responsible kinase, and phosphopeptide mapping pinpointed serine 303. Phorbol ester treatment of ME180 cells increased EGP-1 phosphorylation, implicating PKC-mediated phosphorylation in signal transduction.","method":"Metabolic 32P-labeling, immunoprecipitation, in vitro PKC/PKA kinase assays, phosphoamino acid analysis, phosphopeptide mapping","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase reconstitution plus phosphopeptide mapping identifying specific residue, supported by in vivo phorbol ester experiment","pmids":["7635574"],"is_preprint":false},{"year":2010,"finding":"Trop2 expression activates the ERK MAPK pathway, increasing phospho-ERK1/2 levels, upregulating cyclin D1 and cyclin E, and downregulating p27, thereby promoting cell cycle progression, proliferation, foci formation, anchorage-independent growth, and metastasis in pancreatic cancer models.","method":"Overexpression/knockdown in murine and human cancer cell lines, western blotting for phospho-ERK1/2 and cell cycle proteins, subcutaneous and orthotopic tumor models, liver metastasis assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean gain/loss-of-function with defined pathway readout in multiple cell lines and in vivo models, single lab","pmids":["20858281"],"is_preprint":false},{"year":2013,"finding":"miR-125b-1 directly targets and suppresses TACSTD2 expression; loss of miR-125b-1 (associated with promoter hypermethylation in HNSCC) leads to TACSTD2 upregulation, which drives MAPK pathway dysfunction, contributing to head and neck squamous cell carcinoma pathogenesis.","method":"miRNA profiling, luciferase reporter validation, methylation analysis, TACSTD2 mRNA/protein measurement in cell lines and clinical samples","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct target validation with reporter assay, methylation confirmed, single lab","pmids":["23416980"],"is_preprint":false},{"year":2014,"finding":"Loss of TACSTD2 in squamous cell carcinoma (SCC) attenuates chemotherapeutic agent-induced apoptosis by reducing TAp63-dependent apoptotic gene expression; TACSTD2 knockdown significantly inhibited drug-induced apoptosis, and TACSTD2 was found to regulate apoptotic gene expression through TAp63.","method":"Immunohistochemistry of SCC tissues, siRNA knockdown of TACSTD2 in cell lines, apoptosis assays with chemotherapeutic reagents, western blot for TAp63 and apoptotic genes","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined apoptotic phenotype and transcription factor pathway placement, single lab","pmids":["24651436"],"is_preprint":false},{"year":2016,"finding":"v-Src induces nuclear accumulation of the Trop2 intracellular domain (Trop2 ICD) via cyclin D1; cyclin D1 upregulates components of the Trop2 proteolytic activation complex (PS2, TACE/ADAM17) and represses the inhibitory component Numb, thereby enhancing γ-secretase-mediated cleavage of Trop2 and release of Trop2 ICD, which promotes prostate cancer stem cell self-renewal.","method":"v-Src transformation of primary murine prostate epithelial cells, prostatosphere formation assays, western blotting for PS2/TACE/Numb, immunofluorescence for nuclear Trop2 ICD, cyclin D1 overexpression/knockdown, patient tissue analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis and gain/loss-of-function establishing cyclin D1 as transducer of Src-to-Trop2 ICD cleavage, multiple orthogonal methods, single lab","pmids":["27634768"],"is_preprint":false},{"year":2018,"finding":"TACSTD2/TROP2 interacts with CLDN1 (claudin-1) and OCLN (occludin) and regulates their cellular localization via phosphorylation; TACSTD2 silencing disrupts the linear membrane distribution of CLDN1 and OCLN in hepatoma cells and primary human hepatocytes, and dramatically inhibits HCV entry at the viral entry step.","method":"siRNA silencing of TACSTD2 in hepatoma cell lines and primary human hepatocytes, immunofluorescence for CLDN1/OCLN localization, phosphorylation analysis, HCV infection assays across genotypes","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined localization phenotype and mechanistic link to claudin/occludin phosphorylation and HCV entry, single lab","pmids":["29538454"],"is_preprint":false},{"year":2018,"finding":"TROP2 promotes glioblastoma cell proliferation and metastasis by activating the JAK2/STAT3 signaling pathway; knockdown of TROP2 reduced JAK2 and STAT3 phosphorylation and decreased STAT3 target gene transcription, while JAK2/STAT3 inhibitor WP1066 negated TROP2 overexpression effects, and exogenous IL-6 rescued JAK2/STAT3 phosphorylation in TROP2-silenced cells.","method":"siRNA knockdown, overexpression, MTT/BrdU proliferation assays, Transwell migration, western blot for phospho-JAK2/STAT3, pharmacological inhibition with WP1066, IL-6 rescue experiment","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via pharmacological inhibition and rescue experiment places TROP2 upstream of JAK2/STAT3, single lab with multiple orthogonal methods","pmids":["30431125"],"is_preprint":false},{"year":2018,"finding":"TROP2 promotes osteosarcoma cell proliferation and migration via activation of the PI3K/AKT signaling pathway; overexpression of TROP2 significantly activated PI3K/AKT, while knockdown decreased cell growth and migration.","method":"Overexpression and knockdown in osteosarcoma cell lines, proliferation and migration assays, western blot for PI3K/AKT pathway components","journal":"Molecular medicine reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single set of methods, no upstream/downstream pathway validation beyond correlation","pmids":["29845216"],"is_preprint":false},{"year":2020,"finding":"Matriptase cleaves TROP2 in vitro when purified recombinant proteins are mixed, and TROP2 is cleaved in 293T cells upon co-transfection with matriptase but not with protease-disabled matriptase or the G827R ichthyosis mutant; in keratinocytes (HaCaT cells), siRNA knockdown of HAI-1 (but not HAI-2 alone) promotes endogenous TROP2 cleavage, and combined EpCAM+TROP2 knockdown markedly reduces claudin-1 and claudin-7 levels (partly reversed by chloroquine), establishing TROP2 and EpCAM as redundant regulators of claudin stability downstream of HAI/matriptase.","method":"In vitro reconstitution with purified proteins, co-transfection of 293T cells, siRNA knockdown in HaCaT keratinocytes, western blotting for cleaved TROP2/EpCAM fragments, claudin levels, lysosomal inhibitor (chloroquine) treatment","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified proteins confirmed cleavage, complemented by cell-based co-transfection with active-site mutant controls and siRNA epistasis, multiple orthogonal methods in one study","pmids":["32326212"],"is_preprint":false},{"year":2020,"finding":"Trop2 promotes intracellular calcium ion release in OSCC cells, drives cell cycle progression to S phase, and inhibits P16 expression through the AMPK pathway; Trop2-mediated Ca2+ release was mechanistically linked to AMPK-dependent suppression of P16.","method":"Calcium ion release assays, cell cycle analysis, P16 overexpression rescue, western blot for AMPK pathway, knockdown/overexpression in OSCC cell lines","journal":"International journal of biological macromolecules","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, limited mechanistic depth for AMPK-P16 link, P16 overexpression could not rescue Trop2 effects","pmids":["32768481"],"is_preprint":false},{"year":2021,"finding":"Trop-2 undergoes proteolytic cleavage in the first thyroglobulin domain loop between residues R87 and T88 by ADAM10; coimmunoprecipitation and mass spectrometry revealed physical interaction of ADAM10 with Trop-2; ADAM10 inhibitors, siRNAs, and shRNAs abolished Trop-2 processing; the R87A-T88A mutant abolished xenograft metastatic dissemination, and the cleavage activates cancer growth and metastasis.","method":"Antibody targeting and N-terminal Edman degradation (cleavage site identification), molecular modeling, coimmunoprecipitation + mass spectrometry, immunofluorescence/confocal time-lapse, ADAM10 inhibitors, siRNA/shRNA knockdown, site-directed mutagenesis (R87A-T88A), xenograft metastasis model","journal":"Neoplasia (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — cleavage site identified by Edman degradation, effector protease identified by Co-IP+MS and multiple genetic/pharmacological approaches, functional validation with site mutant in vivo, multiple orthogonal methods","pmids":["33839455"],"is_preprint":false},{"year":2022,"finding":"EPCAM and TROP2 share redundant roles in stabilizing claudin-7 at cell membranes and supporting epithelial development; TROP2 deficiency in mice compounded EPCAM-deficiency phenotypes (reduced embryonic viability, shortened postnatal lifespan, loss of claudin-7 membrane localization), and TROP2 could compensate for EPCAM loss in claudin-7 stabilization in tissues co-expressing both proteins.","method":"EPCAM and TROP2 knockout mouse models, histology/immunofluorescence, claudin-7 protein localization and expression analysis in multiple tissues","journal":"Biology open","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in double-knockout mouse model with defined molecular phenotype (claudin-7 stabilization), replicated across multiple tissue types","pmids":["35730316"],"is_preprint":false},{"year":2022,"finding":"TROP2 translation is enhanced by dual RNA modifications: METTL3-mediated m6A methylation of TROP2 mRNA promotes its translation, and METTL1-mediated m7G modification of specific tRNAs further enhances TROP2 protein production; METTL3/METTL1 double knockout inhibited bladder cancer proliferation/invasion, and TROP2 overexpression partially rescued this phenotype.","method":"m6A/m7G methylation assays, METTL3/METTL1 knockout (CRISPR), TROP2 overexpression rescue, in vitro and in vivo proliferation/invasion assays, RNA immunoprecipitation","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual epistasis with rescue experiment, mechanistic link established between two RNA modifications and TROP2 protein level, single lab","pmids":["37268280"],"is_preprint":false},{"year":2023,"finding":"Trop2 promotes breast cancer metastasis through a Trop2/β-catenin positive feedback loop; Trop2 physically complexes with β-catenin (identified by immunoprecipitation and mass spectrometry), preventing β-catenin ubiquitin-proteasome degradation and enabling nuclear translocation to transcribe Trop2. Bruceine D binds Trop2 at Lys307 and Glu310 (validated by cellular thermal shift assay and point mutation analyses), disrupts the complex, destabilizes β-catenin, and inhibits EMT and ECM remodeling.","method":"Cell membrane chromatography screening, cellular thermal shift assay, point mutation analysis (Lys307/Glu310), immunoprecipitation + mass spectrometry, immunofluorescence, western blot, orthotopic metastasis model","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding site validated by mutagenesis + CETSA, Co-IP+MS for complex, in vivo metastasis model, single lab","pmids":["37271476"],"is_preprint":false},{"year":2022,"finding":"TROP2 physically interacts with DSG2 (desmoglein-2) in gastric cancer cells (identified by co-immunoprecipitation and mass spectrometry); TROP2 overexpression reduces DSG2 levels and desmosome assembly, increasing cell invasion and migration via EGFR/AKT and DSG2/plakoglobin/β-catenin pathways.","method":"Co-immunoprecipitation, mass spectrometry, TROP2 overexpression and knockdown, electron microscopy for desmosome assembly, western blot for EGFR/AKT and DSG2/PG/β-catenin pathway proteins, adhesion and invasion assays","journal":"Current cancer drug targets","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP+MS for interaction, functional gain/loss-of-function with pathway readout, single lab","pmids":["35392784"],"is_preprint":false},{"year":2004,"finding":"The TACSTD2/M1S1 C108R missense mutation causes the protein to be distributed diffusely in the cytoplasm rather than accumulating at cell-to-cell adhesion borders (as normal TACSTD2 does), demonstrating that the transmembrane/cytoplasmic domain is required for proper membrane localization.","method":"Expression vectors for normal and C108R-mutant M1S1 transfected into CHO cells, immunofluorescence localization","journal":"Japanese journal of ophthalmology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment in transfected cells comparing wild-type vs. disease mutant, single lab","pmids":["15295654"],"is_preprint":false},{"year":2012,"finding":"A GDLD patient-derived conjunctival epithelial cell line lacking functional TACSTD2 has significantly reduced tight junction protein expression and markedly lower transepithelial resistance compared to normal conjunctival epithelial cells, establishing TACSTD2 as necessary for epithelial barrier function.","method":"Immortalized patient cell line (lentiviral SV40T/hTERT), protein expression analysis of tight junction proteins, transepithelial resistance (TER) measurements","journal":"Transactions of the American Ophthalmological Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional loss-of-function cell line with TER as defined physiological readout, single lab","pmids":["23818740"],"is_preprint":false},{"year":2023,"finding":"TACSTD2 promotes platinum resistance in high-grade serous ovarian cancer via the Rap1/PI3K/AKT pathway; RNA-seq analysis of a TACSTD2-representative cisplatin-resistant epithelial subcluster (E0) identified this pathway as the mechanistic basis.","method":"Single-cell RNA sequencing, spatial transcriptomics, RNA-seq pathway analysis, TACSTD2 functional analysis in cell lines","journal":"Journal of Cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement based primarily on transcriptomic analysis with limited direct functional validation of the specific pathway","pmids":["38817863"],"is_preprint":false},{"year":2023,"finding":"TACSTD2 expression in breast cancer cells is regulated by transcription factor EB (TFEB): tamoxifen induces TFEB dephosphorylation (active form), and active TFEB drives TACSTD2 transcription through a tandem E-box motif in the Trop2 promoter; TFEB depletion prevented tamoxifen-induced Trop2 upregulation.","method":"TFEB knockdown, luciferase reporter assay with Trop2 promoter E-box motif, western blotting for phospho-TFEB, kinase inhibitor panel, RT-qPCR/western blot for Trop2","journal":"Breast cancer (Tokyo, Japan)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with defined promoter element plus siRNA epistasis identifies TFEB as transcriptional activator, single lab","pmids":["35882754"],"is_preprint":false}],"current_model":"TACSTD2/TROP2 is a type I transmembrane glycoprotein that transduces intracellular calcium signals and is phosphorylated on Ser303 by protein kinase C; it is proteolytically activated by ADAM10 cleavage (at R87-T88) and by γ-secretase/TACE (releasing the intracellular domain whose nuclear accumulation is amplified by cyclin D1 downstream of Src), cleaved by matriptase (regulated by HAI inhibitors), and physically interacts with claudins, CLDN1/OCLN (regulating their membrane localization and tight junction barrier function), DSG2 (modulating desmosome assembly and EGFR/AKT signaling), and β-catenin (preventing its proteasomal degradation to form a positive feedback loop driving EMT); it signals through ERK MAPK, PI3K/AKT, JAK2/STAT3, and AMPK pathways to promote proliferation, cell cycle progression, survival, invasion, and metastasis, while its expression is transcriptionally regulated by miR-125b-1 and TFEB (via a promoter E-box motif) and translationally enhanced by METTL3/METTL1-mediated dual m6A/m7G RNA modifications."},"narrative":{"mechanistic_narrative":"TACSTD2 (TROP2) is a type I transmembrane glycoprotein that functions both as an epithelial cell-surface signal transducer and as a regulator of intercellular junction integrity, with prominent roles in carcinoma proliferation, survival, and metastasis [PMID:20858281, PMID:35730316]. At the membrane it physically partners with tight-junction proteins claudin-1 and occludin and controls their localization and phosphorylation, and acts redundantly with EpCAM to stabilize claudin-7 at cell membranes during epithelial development, such that loss of TACSTD2 disrupts barrier function [PMID:29538454, PMID:32326212, PMID:35730316]. Its activity is gated by sequential proteolysis: ADAM10 cleaves TROP2 within the first thyroglobulin-domain loop between R87 and T88 to drive metastatic dissemination, matriptase (restrained by the HAI-1 inhibitor) cleaves it in keratinocytes, and Src-induced cyclin D1 amplifies γ-secretase/TACE-mediated release of a TROP2 intracellular domain that accumulates in the nucleus to promote cancer stem-cell self-renewal [PMID:33839455, PMID:32326212, PMID:27634768]. The cytoplasmic tail is phosphorylated on Ser303 by protein kinase C, and TROP2 raises intracellular calcium and signals through ERK MAPK, PI3K/AKT, and JAK2/STAT3 cascades to upregulate cyclins D1/E, suppress p27 and p16, and drive cell-cycle progression, invasion, and apoptosis resistance [PMID:7635574, PMID:20858281, PMID:30431125, PMID:29845216, PMID:32768481]. TROP2 also complexes with β-catenin to block its proteasomal degradation, forming a positive feedback loop that sustains TROP2 transcription and EMT, and engages DSG2 to remodel desmosomes via EGFR/AKT signaling [PMID:37271476, PMID:35392784]. TROP2 abundance is set by miR-125b-1 silencing, TFEB-driven transcription through a promoter E-box, and METTL3/METTL1 dual m6A/m7G RNA modification of its mRNA and tRNAs [PMID:23416980, PMID:35882754, PMID:37268280]. Mutations in TACSTD2 that mislocalize the protein and abolish epithelial barrier function underlie gelatinous drop-like corneal dystrophy [PMID:15295654, PMID:23818740].","teleology":[{"year":1995,"claim":"Established that the TROP2 cytoplasmic tail is a substrate for intracellular signaling kinases, providing the first evidence that this surface glycoprotein transduces signals rather than acting purely structurally.","evidence":"In vitro PKC/PKA kinase assays with phosphopeptide mapping and in vivo 32P-labeling in ME180 cells","pmids":["7635574"],"confidence":"High","gaps":["Downstream consequences of Ser303 phosphorylation not defined","No link to a specific signaling cascade established at this stage"]},{"year":2004,"claim":"Linked TACSTD2 to corneal dystrophy mechanistically by showing a disease mutation mislocalizes the protein away from cell-cell borders, implicating the transmembrane/cytoplasmic domain in proper membrane targeting.","evidence":"Immunofluorescence of wild-type vs C108R-mutant M1S1 in transfected CHO cells","pmids":["15295654"],"confidence":"Medium","gaps":["Single ectopic expression system","Functional consequence for junctions not measured in this study"]},{"year":2010,"claim":"Defined the first concrete pro-tumorigenic signaling output of TROP2 by placing it upstream of ERK-driven cell-cycle progression.","evidence":"Gain/loss-of-function in pancreatic cancer cell lines with phospho-ERK/cyclin western blots and in vivo metastasis models","pmids":["20858281"],"confidence":"Medium","gaps":["Mechanism connecting surface TROP2 to ERK activation unresolved","Single lab"]},{"year":2013,"claim":"Identified an upstream regulatory layer controlling TROP2 levels, showing miR-125b-1 loss derepresses TACSTD2 to drive MAPK dysfunction in HNSCC.","evidence":"miRNA profiling, luciferase reporter validation, and methylation analysis in cell lines and clinical samples","pmids":["23416980"],"confidence":"Medium","gaps":["Other regulators of TACSTD2 expression not addressed","Single lab"]},{"year":2014,"claim":"Connected TROP2 to chemoresistance by showing it sustains TAp63-dependent apoptotic gene programs, framing TROP2 loss as a route to apoptosis evasion.","evidence":"siRNA knockdown in SCC lines with drug-induced apoptosis assays and TAp63 western blots","pmids":["24651436"],"confidence":"Medium","gaps":["Direct molecular link between TROP2 and TAp63 not defined","Single lab"]},{"year":2016,"claim":"Resolved how oncogenic Src triggers TROP2 intracellular-domain signaling, identifying cyclin D1 as the transducer that promotes γ-secretase cleavage and nuclear ICD accumulation driving stem-cell self-renewal.","evidence":"v-Src transformation of prostate epithelial cells, prostatosphere assays, cyclin D1 epistasis, and ICD immunofluorescence","pmids":["27634768"],"confidence":"Medium","gaps":["Nuclear targets of the TROP2 ICD not identified","Single lab"]},{"year":2018,"claim":"Demonstrated TROP2 governs tight-junction protein localization, showing it controls CLDN1/OCLN membrane distribution via phosphorylation and is required for HCV entry.","evidence":"siRNA silencing in hepatoma lines and primary hepatocytes with CLDN1/OCLN immunofluorescence and HCV infection assays","pmids":["29538454"],"confidence":"Medium","gaps":["Kinase responsible for claudin/occludin phosphorylation not identified","Single lab"]},{"year":2018,"claim":"Extended TROP2 signaling to the JAK2/STAT3 axis through pharmacological and cytokine rescue epistasis in glioblastoma.","evidence":"Knockdown/overexpression with WP1066 inhibition and IL-6 rescue, phospho-JAK2/STAT3 western blots","pmids":["30431125"],"confidence":"Medium","gaps":["Direct biochemical coupling of TROP2 to JAK2 unresolved","Single lab"]},{"year":2018,"claim":"Associated TROP2 with PI3K/AKT activation in osteosarcoma proliferation and migration.","evidence":"Overexpression/knockdown in osteosarcoma lines with PI3K/AKT western blots and proliferation/migration assays","pmids":["29845216"],"confidence":"Low","gaps":["No upstream/downstream pathway validation beyond correlation","Single lab, single method set"]},{"year":2020,"claim":"Established matriptase as a TROP2 protease and positioned TROP2 with EpCAM as redundant HAI/matriptase-regulated stabilizers of claudins.","evidence":"In vitro reconstitution with purified proteins, 293T co-transfection with active-site/mutant controls, and HAI-1 siRNA epistasis in keratinocytes","pmids":["32326212"],"confidence":"High","gaps":["Physiological setting of matriptase cleavage in vivo not established","Cleavage site within TROP2 not mapped here"]},{"year":2020,"claim":"Linked TROP2-driven calcium release to AMPK-dependent p16 suppression and S-phase entry in OSCC.","evidence":"Calcium release assays, cell cycle analysis, P16 rescue, and AMPK western blots in OSCC lines","pmids":["32768481"],"confidence":"Low","gaps":["P16 overexpression could not rescue TROP2 effects, weakening the causal chain","AMPK-P16 mechanism shallow","Single lab"]},{"year":2021,"claim":"Identified the principal activating protease and cleavage site, showing ADAM10 cuts TROP2 between R87-T88 and that an uncleavable mutant abolishes metastatic dissemination.","evidence":"Edman degradation site mapping, Co-IP+MS, ADAM10 inhibitor/siRNA/shRNA, R87A-T88A mutagenesis, and xenograft metastasis model","pmids":["33839455"],"confidence":"High","gaps":["Signaling events downstream of cleavage incompletely defined","Single lab"]},{"year":2022,"claim":"Provided in vivo genetic confirmation that TROP2 and EpCAM are functionally redundant in stabilizing claudin-7 and supporting epithelial development.","evidence":"EPCAM/TROP2 single and double knockout mouse models with claudin-7 localization analysis across tissues","pmids":["35730316"],"confidence":"High","gaps":["Molecular mechanism of claudin-7 stabilization not resolved","Tissue-specific contributions not fully dissected"]},{"year":2022,"claim":"Identified DSG2 as a TROP2 physical partner and a route by which TROP2 destabilizes desmosomes to drive invasion via EGFR/AKT signaling.","evidence":"Co-IP+MS, gain/loss-of-function, electron microscopy of desmosomes, and pathway western blots in gastric cancer cells","pmids":["35392784"],"confidence":"Medium","gaps":["Interaction interface not mapped","Single lab"]},{"year":2022,"claim":"Defined TFEB as a transcriptional activator of TACSTD2, showing tamoxifen-induced active TFEB drives Trop2 expression through a promoter E-box.","evidence":"TFEB knockdown, Trop2 promoter E-box luciferase reporter, and phospho-TFEB western blots in breast cancer cells","pmids":["35882754"],"confidence":"Medium","gaps":["Broader signaling context of TFEB-TROP2 axis not defined","Single lab"]},{"year":2022,"claim":"Revealed post-transcriptional control of TROP2 protein output through dual m6A/m7G RNA modifications.","evidence":"METTL3/METTL1 CRISPR knockout, m6A/m7G assays, RNA-IP, and TROP2 overexpression rescue in bladder cancer","pmids":["37268280"],"confidence":"Medium","gaps":["Relative contribution of m6A vs m7G to TROP2 levels not quantified","Single lab"]},{"year":2023,"claim":"Uncovered a TROP2/β-catenin positive feedback loop that stabilizes β-catenin and sustains TROP2 transcription to drive EMT and metastasis.","evidence":"Co-IP+MS, CETSA and Lys307/Glu310 mutagenesis with the inhibitor Bruceine D, and orthotopic metastasis model","pmids":["37271476"],"confidence":"Medium","gaps":["Mechanism by which TROP2 blocks β-catenin ubiquitination not detailed","Single lab"]},{"year":2023,"claim":"Associated TACSTD2 with platinum resistance in ovarian cancer via the Rap1/PI3K/AKT pathway.","evidence":"Single-cell RNA-seq, spatial transcriptomics, and pathway analysis with functional analysis in cell lines","pmids":["38817863"],"confidence":"Low","gaps":["Pathway placement rests largely on transcriptomics","Limited direct functional validation"]},{"year":null,"claim":"How the multiple TROP2 proteolytic events, junctional interactions, and intracellular signaling cascades are integrated into a single coherent regulatory program — and which kinase mediates TROP2-dependent claudin/occludin phosphorylation — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking ICD nuclear signaling to surface junction regulation","Kinase for claudin/occludin phosphorylation unidentified","Structural basis of partner interactions not solved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,6,9]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[5,11,16]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,8,11,15]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,6,7]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,10]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[5,11,16]}],"complexes":[],"partners":["CLDN1","OCLN","CLDN7","EPCAM","DSG2","CTNNB1","ADAM10","MST1R"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09758","full_name":"Tumor-associated calcium signal transducer 2","aliases":["Cell surface glycoprotein Trop-2","Membrane component chromosome 1 surface marker 1","Pancreatic carcinoma marker protein GA733-1"],"length_aa":323,"mass_kda":35.7,"function":"May function as a growth factor receptor","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P09758/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TACSTD2","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TACSTD2","total_profiled":1310},"omim":[{"mim_id":"204870","title":"CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD","url":"https://www.omim.org/entry/204870"},{"mim_id":"185535","title":"EPITHELIAL CELLULAR ADHESION MOLECULE; EPCAM","url":"https://www.omim.org/entry/185535"},{"mim_id":"137290","title":"TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TACSTD2","url":"https://www.omim.org/entry/137290"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":1245.4},{"tissue":"salivary gland","ntpm":585.3},{"tissue":"skin 1","ntpm":554.9}],"url":"https://www.proteinatlas.org/search/TACSTD2"},"hgnc":{"alias_symbol":["TROP2","GA733-1","EGP-1"],"prev_symbol":["M1S1"]},"alphafold":{"accession":"P09758","domains":[{"cath_id":"-","chopping":"34-84_100-149","consensus_level":"medium","plddt":89.9902,"start":34,"end":149},{"cath_id":"3.30.70","chopping":"151-269","consensus_level":"medium","plddt":93.1413,"start":151,"end":269}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09758","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09758-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09758-F1-predicted_aligned_error_v6.png","plddt_mean":82.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TACSTD2","jax_strain_url":"https://www.jax.org/strain/search?query=TACSTD2"},"sequence":{"accession":"P09758","fasta_url":"https://rest.uniprot.org/uniprotkb/P09758.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09758/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09758"}},"corpus_meta":[{"pmid":"26101915","id":"PMC_26101915","title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26101915","citation_count":405,"is_preprint":false},{"pmid":"26000093","id":"PMC_26000093","title":"Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.","date":"2015","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26000093","citation_count":337,"is_preprint":false},{"pmid":"34413126","id":"PMC_34413126","title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.","date":"2021","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34413126","citation_count":269,"is_preprint":false},{"pmid":"29989029","id":"PMC_29989029","title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29989029","citation_count":263,"is_preprint":false},{"pmid":"21551320","id":"PMC_21551320","title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.","date":"2011","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/21551320","citation_count":213,"is_preprint":false},{"pmid":"20858281","id":"PMC_20858281","title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20858281","citation_count":189,"is_preprint":false},{"pmid":"19683559","id":"PMC_19683559","title":"Trop2: a possible therapeutic target for late stage epithelial carcinomas.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19683559","citation_count":158,"is_preprint":false},{"pmid":"30881031","id":"PMC_30881031","title":"Targeting Trop-2 in solid tumors: future prospects.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30881031","citation_count":143,"is_preprint":false},{"pmid":"31208270","id":"PMC_31208270","title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.","date":"2019","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/31208270","citation_count":132,"is_preprint":false},{"pmid":"33187148","id":"PMC_33187148","title":"Trop2: Jack of All Trades, Master of None.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33187148","citation_count":116,"is_preprint":false},{"pmid":"36302269","id":"PMC_36302269","title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.","date":"2022","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/36302269","citation_count":114,"is_preprint":false},{"pmid":"36208791","id":"PMC_36208791","title":"Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.","date":"2022","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36208791","citation_count":105,"is_preprint":false},{"pmid":"25523132","id":"PMC_25523132","title":"Trop2: from development to disease.","date":"2015","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/25523132","citation_count":99,"is_preprint":false},{"pmid":"22482828","id":"PMC_22482828","title":"Significance of EpCAM and TROP2 expression in non-small cell lung cancer.","date":"2012","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22482828","citation_count":86,"is_preprint":false},{"pmid":"37121444","id":"PMC_37121444","title":"Targeting Trop-2 in cancer: Recent research progress and clinical application.","date":"2023","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37121444","citation_count":80,"is_preprint":false},{"pmid":"35216942","id":"PMC_35216942","title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.","date":"2022","source":"European urology oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35216942","citation_count":79,"is_preprint":false},{"pmid":"36620535","id":"PMC_36620535","title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36620535","citation_count":78,"is_preprint":false},{"pmid":"7635574","id":"PMC_7635574","title":"The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.","date":"1995","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7635574","citation_count":76,"is_preprint":false},{"pmid":"36497418","id":"PMC_36497418","title":"Trop-2 as a Therapeutic Target in Breast Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36497418","citation_count":73,"is_preprint":false},{"pmid":"23416980","id":"PMC_23416980","title":"Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23416980","citation_count":69,"is_preprint":false},{"pmid":"38948057","id":"PMC_38948057","title":"Trop2-targeted therapies in solid tumors: advances and future directions.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38948057","citation_count":64,"is_preprint":false},{"pmid":"36153494","id":"PMC_36153494","title":"Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36153494","citation_count":64,"is_preprint":false},{"pmid":"33839455","id":"PMC_33839455","title":"Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.","date":"2021","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33839455","citation_count":52,"is_preprint":false},{"pmid":"37932752","id":"PMC_37932752","title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.","date":"2023","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37932752","citation_count":50,"is_preprint":false},{"pmid":"36939530","id":"PMC_36939530","title":"Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/36939530","citation_count":50,"is_preprint":false},{"pmid":"38048058","id":"PMC_38048058","title":"TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38048058","citation_count":49,"is_preprint":false},{"pmid":"30431125","id":"PMC_30431125","title":"TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30431125","citation_count":48,"is_preprint":false},{"pmid":"29901071","id":"PMC_29901071","title":"Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29901071","citation_count":47,"is_preprint":false},{"pmid":"26773504","id":"PMC_26773504","title":"TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26773504","citation_count":47,"is_preprint":false},{"pmid":"35789445","id":"PMC_35789445","title":"Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.","date":"2022","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/35789445","citation_count":46,"is_preprint":false},{"pmid":"37977513","id":"PMC_37977513","title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma.","date":"2023","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37977513","citation_count":44,"is_preprint":false},{"pmid":"31674732","id":"PMC_31674732","title":"Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31674732","citation_count":43,"is_preprint":false},{"pmid":"38565806","id":"PMC_38565806","title":"ImmunoPET imaging of Trop2 in patients with solid tumours.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38565806","citation_count":40,"is_preprint":false},{"pmid":"38196202","id":"PMC_38196202","title":"Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.","date":"2024","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/38196202","citation_count":39,"is_preprint":false},{"pmid":"21865288","id":"PMC_21865288","title":"Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.","date":"2011","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21865288","citation_count":38,"is_preprint":false},{"pmid":"39135109","id":"PMC_39135109","title":"Trop2-targeted therapy in breast cancer.","date":"2024","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/39135109","citation_count":37,"is_preprint":false},{"pmid":"35530278","id":"PMC_35530278","title":"Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35530278","citation_count":36,"is_preprint":false},{"pmid":"29538454","id":"PMC_29538454","title":"Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29538454","citation_count":34,"is_preprint":false},{"pmid":"37230055","id":"PMC_37230055","title":"TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).","date":"2023","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37230055","citation_count":32,"is_preprint":false},{"pmid":"35735421","id":"PMC_35735421","title":"Trop-2 in Upper Tract Urothelial Carcinoma.","date":"2022","source":"Current oncology (Toronto, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/35735421","citation_count":32,"is_preprint":false},{"pmid":"32326212","id":"PMC_32326212","title":"Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32326212","citation_count":31,"is_preprint":false},{"pmid":"37271476","id":"PMC_37271476","title":"Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/β-catenin positive feedback loop.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37271476","citation_count":30,"is_preprint":false},{"pmid":"29845216","id":"PMC_29845216","title":"TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29845216","citation_count":30,"is_preprint":false},{"pmid":"38760413","id":"PMC_38760413","title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.","date":"2024","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38760413","citation_count":29,"is_preprint":false},{"pmid":"37792026","id":"PMC_37792026","title":"ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/37792026","citation_count":29,"is_preprint":false},{"pmid":"30010814","id":"PMC_30010814","title":"Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30010814","citation_count":29,"is_preprint":false},{"pmid":"37344281","id":"PMC_37344281","title":"Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.","date":"2023","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37344281","citation_count":29,"is_preprint":false},{"pmid":"39509246","id":"PMC_39509246","title":"68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/39509246","citation_count":27,"is_preprint":false},{"pmid":"23397225","id":"PMC_23397225","title":"TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.","date":"2013","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/23397225","citation_count":26,"is_preprint":false},{"pmid":"11687514","id":"PMC_11687514","title":"A novel mutation in the M1S1 gene responsible for gelatinous droplike corneal dystrophy.","date":"2001","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11687514","citation_count":25,"is_preprint":false},{"pmid":"37567892","id":"PMC_37567892","title":"Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.","date":"2023","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37567892","citation_count":25,"is_preprint":false},{"pmid":"39555080","id":"PMC_39555080","title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39555080","citation_count":24,"is_preprint":false},{"pmid":"30002602","id":"PMC_30002602","title":"TROP2 methylation and expression in tamoxifen-resistant breast cancer.","date":"2018","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/30002602","citation_count":24,"is_preprint":false},{"pmid":"11004271","id":"PMC_11004271","title":"Q118X mutation of M1S1 gene caused gelatinous drop-like corneal dystrophy: the P501T of BIGH3 gene found in a family with gelatinous drop-like corneal dystrophy.","date":"2000","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/11004271","citation_count":23,"is_preprint":false},{"pmid":"36995069","id":"PMC_36995069","title":"Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.","date":"2023","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36995069","citation_count":23,"is_preprint":false},{"pmid":"37268280","id":"PMC_37268280","title":"TROP2 translation mediated by dual m6A/m7G RNA modifications promotes bladder cancer development.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37268280","citation_count":22,"is_preprint":false},{"pmid":"12614764","id":"PMC_12614764","title":"A novel mutation of M1S1 gene found in a Vietnamese patient with gelatinous droplike corneal dystrophy.","date":"2003","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12614764","citation_count":22,"is_preprint":false},{"pmid":"40086591","id":"PMC_40086591","title":"Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management.","date":"2025","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/40086591","citation_count":21,"is_preprint":false},{"pmid":"38179054","id":"PMC_38179054","title":"Targeting Trop2 in solid tumors: a look into structures and novel epitopes.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38179054","citation_count":21,"is_preprint":false},{"pmid":"39525044","id":"PMC_39525044","title":"Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment.","date":"2024","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39525044","citation_count":21,"is_preprint":false},{"pmid":"35962580","id":"PMC_35962580","title":"TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.","date":"2022","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/35962580","citation_count":21,"is_preprint":false},{"pmid":"17167402","id":"PMC_17167402","title":"A novel TACSTD2 gene mutation in a Turkish family with a gelatinous drop-like corneal dystrophy.","date":"2006","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/17167402","citation_count":21,"is_preprint":false},{"pmid":"27634768","id":"PMC_27634768","title":"v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27634768","citation_count":20,"is_preprint":false},{"pmid":"24651436","id":"PMC_24651436","title":"Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24651436","citation_count":19,"is_preprint":false},{"pmid":"36878461","id":"PMC_36878461","title":"Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma.","date":"2023","source":"Clinics and research in hepatology and gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36878461","citation_count":18,"is_preprint":false},{"pmid":"39413161","id":"PMC_39413161","title":"Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39413161","citation_count":17,"is_preprint":false},{"pmid":"35882754","id":"PMC_35882754","title":"Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.","date":"2022","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/35882754","citation_count":17,"is_preprint":false},{"pmid":"38020299","id":"PMC_38020299","title":"Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38020299","citation_count":17,"is_preprint":false},{"pmid":"32768481","id":"PMC_32768481","title":"Trop2 inhibition of P16 expression and the cell cycle promotes intracellular calcium release in OSCC.","date":"2020","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32768481","citation_count":17,"is_preprint":false},{"pmid":"35730316","id":"PMC_35730316","title":"EPCAM and TROP2 share a role in claudin stabilization and development of intestinal and extraintestinal epithelia in mice.","date":"2022","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/35730316","citation_count":17,"is_preprint":false},{"pmid":"37954074","id":"PMC_37954074","title":"Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37954074","citation_count":16,"is_preprint":false},{"pmid":"15013888","id":"PMC_15013888","title":"Compound heterozygous mutations of M1S1 gene in gelatinous droplike corneal dystrophy.","date":"2004","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/15013888","citation_count":16,"is_preprint":false},{"pmid":"34280931","id":"PMC_34280931","title":"The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.","date":"2021","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34280931","citation_count":16,"is_preprint":false},{"pmid":"40517574","id":"PMC_40517574","title":"Evolution of TROP2: Biological insights and clinical applications.","date":"2025","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40517574","citation_count":15,"is_preprint":false},{"pmid":"39994021","id":"PMC_39994021","title":"ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab')2.","date":"2025","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/39994021","citation_count":15,"is_preprint":false},{"pmid":"38723340","id":"PMC_38723340","title":"Trop-2 expression and the tumor immune microenvironment in cervical cancer.","date":"2024","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38723340","citation_count":15,"is_preprint":false},{"pmid":"35392784","id":"PMC_35392784","title":"TROP2 Down-regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR/AKT and DSG2/PG/β-Catenin Pathways.","date":"2022","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/35392784","citation_count":15,"is_preprint":false},{"pmid":"34299325","id":"PMC_34299325","title":"Trop2 Expression in Extramammary Paget's Disease and Normal Skin.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299325","citation_count":14,"is_preprint":false},{"pmid":"20454699","id":"PMC_20454699","title":"Identification and characterization of a novel TACSTD2 mutation in gelatinous drop-like corneal dystrophy.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20454699","citation_count":14,"is_preprint":false},{"pmid":"32854652","id":"PMC_32854652","title":"Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32854652","citation_count":14,"is_preprint":false},{"pmid":"38203255","id":"PMC_38203255","title":"The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203255","citation_count":14,"is_preprint":false},{"pmid":"39537365","id":"PMC_39537365","title":"Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.","date":"2024","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/39537365","citation_count":13,"is_preprint":false},{"pmid":"39585341","id":"PMC_39585341","title":"Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.","date":"2025","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39585341","citation_count":13,"is_preprint":false},{"pmid":"38981151","id":"PMC_38981151","title":"Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.","date":"2024","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38981151","citation_count":13,"is_preprint":false},{"pmid":"10937555","id":"PMC_10937555","title":"Rapid detection of M1S1 mutations by the protein truncation test.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10937555","citation_count":13,"is_preprint":false},{"pmid":"24816726","id":"PMC_24816726","title":"Trop2 gene: a novel target for cervical cancer treatment.","date":"2014","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24816726","citation_count":13,"is_preprint":false},{"pmid":"39786401","id":"PMC_39786401","title":"OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.","date":"2025","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39786401","citation_count":12,"is_preprint":false},{"pmid":"39542697","id":"PMC_39542697","title":"Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation.","date":"2024","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39542697","citation_count":12,"is_preprint":false},{"pmid":"33815794","id":"PMC_33815794","title":"Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer.","date":"2021","source":"Molecular and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33815794","citation_count":12,"is_preprint":false},{"pmid":"38817863","id":"PMC_38817863","title":"Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38817863","citation_count":12,"is_preprint":false},{"pmid":"39841860","id":"PMC_39841860","title":"Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors.","date":"2025","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39841860","citation_count":12,"is_preprint":false},{"pmid":"37014471","id":"PMC_37014471","title":"An assembly of TROP2-mediated signaling events.","date":"2023","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/37014471","citation_count":11,"is_preprint":false},{"pmid":"40059341","id":"PMC_40059341","title":"ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy.","date":"2025","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/40059341","citation_count":11,"is_preprint":false},{"pmid":"33882870","id":"PMC_33882870","title":"DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.","date":"2021","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33882870","citation_count":11,"is_preprint":false},{"pmid":"36527253","id":"PMC_36527253","title":"TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.","date":"2023","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/36527253","citation_count":11,"is_preprint":false},{"pmid":"23818740","id":"PMC_23818740","title":"Establishment of a human conjunctival epithelial cell line lacking the functional TACSTD2 gene (an American Ophthalmological Society thesis).","date":"2012","source":"Transactions of the American Ophthalmological Society","url":"https://pubmed.ncbi.nlm.nih.gov/23818740","citation_count":11,"is_preprint":false},{"pmid":"15295654","id":"PMC_15295654","title":"Mutations in the membrane component, chromosome 1, surface marker 1 (M1S1) gene in gelatinous drop-like corneal dystrophy.","date":"2004","source":"Japanese journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/15295654","citation_count":11,"is_preprint":false},{"pmid":"39564769","id":"PMC_39564769","title":"Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer.","date":"2025","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39564769","citation_count":11,"is_preprint":false},{"pmid":"33289434","id":"PMC_33289434","title":"TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.","date":"2020","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33289434","citation_count":11,"is_preprint":false},{"pmid":"37573703","id":"PMC_37573703","title":"High levels of expression of Trop-2 in thymic epithelial tumors.","date":"2023","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/37573703","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53156,"output_tokens":5435,"usd":0.120497,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13819,"output_tokens":5171,"usd":0.099185,"stage2_stop_reason":"end_turn"},"total_usd":0.219682,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"TACSTD2/EGP-1 is phosphorylated in vivo on serine 303 in its cytoplasmic domain by protein kinase C (PKC); metabolic 32P-labeling and immunoprecipitation confirmed phosphorylation on serine, in vitro kinase assays identified PKC (not PKA) as the responsible kinase, and phosphopeptide mapping pinpointed serine 303. Phorbol ester treatment of ME180 cells increased EGP-1 phosphorylation, implicating PKC-mediated phosphorylation in signal transduction.\",\n      \"method\": \"Metabolic 32P-labeling, immunoprecipitation, in vitro PKC/PKA kinase assays, phosphoamino acid analysis, phosphopeptide mapping\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase reconstitution plus phosphopeptide mapping identifying specific residue, supported by in vivo phorbol ester experiment\",\n      \"pmids\": [\"7635574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Trop2 expression activates the ERK MAPK pathway, increasing phospho-ERK1/2 levels, upregulating cyclin D1 and cyclin E, and downregulating p27, thereby promoting cell cycle progression, proliferation, foci formation, anchorage-independent growth, and metastasis in pancreatic cancer models.\",\n      \"method\": \"Overexpression/knockdown in murine and human cancer cell lines, western blotting for phospho-ERK1/2 and cell cycle proteins, subcutaneous and orthotopic tumor models, liver metastasis assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean gain/loss-of-function with defined pathway readout in multiple cell lines and in vivo models, single lab\",\n      \"pmids\": [\"20858281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-125b-1 directly targets and suppresses TACSTD2 expression; loss of miR-125b-1 (associated with promoter hypermethylation in HNSCC) leads to TACSTD2 upregulation, which drives MAPK pathway dysfunction, contributing to head and neck squamous cell carcinoma pathogenesis.\",\n      \"method\": \"miRNA profiling, luciferase reporter validation, methylation analysis, TACSTD2 mRNA/protein measurement in cell lines and clinical samples\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct target validation with reporter assay, methylation confirmed, single lab\",\n      \"pmids\": [\"23416980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of TACSTD2 in squamous cell carcinoma (SCC) attenuates chemotherapeutic agent-induced apoptosis by reducing TAp63-dependent apoptotic gene expression; TACSTD2 knockdown significantly inhibited drug-induced apoptosis, and TACSTD2 was found to regulate apoptotic gene expression through TAp63.\",\n      \"method\": \"Immunohistochemistry of SCC tissues, siRNA knockdown of TACSTD2 in cell lines, apoptosis assays with chemotherapeutic reagents, western blot for TAp63 and apoptotic genes\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined apoptotic phenotype and transcription factor pathway placement, single lab\",\n      \"pmids\": [\"24651436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"v-Src induces nuclear accumulation of the Trop2 intracellular domain (Trop2 ICD) via cyclin D1; cyclin D1 upregulates components of the Trop2 proteolytic activation complex (PS2, TACE/ADAM17) and represses the inhibitory component Numb, thereby enhancing γ-secretase-mediated cleavage of Trop2 and release of Trop2 ICD, which promotes prostate cancer stem cell self-renewal.\",\n      \"method\": \"v-Src transformation of primary murine prostate epithelial cells, prostatosphere formation assays, western blotting for PS2/TACE/Numb, immunofluorescence for nuclear Trop2 ICD, cyclin D1 overexpression/knockdown, patient tissue analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis and gain/loss-of-function establishing cyclin D1 as transducer of Src-to-Trop2 ICD cleavage, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"27634768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TACSTD2/TROP2 interacts with CLDN1 (claudin-1) and OCLN (occludin) and regulates their cellular localization via phosphorylation; TACSTD2 silencing disrupts the linear membrane distribution of CLDN1 and OCLN in hepatoma cells and primary human hepatocytes, and dramatically inhibits HCV entry at the viral entry step.\",\n      \"method\": \"siRNA silencing of TACSTD2 in hepatoma cell lines and primary human hepatocytes, immunofluorescence for CLDN1/OCLN localization, phosphorylation analysis, HCV infection assays across genotypes\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined localization phenotype and mechanistic link to claudin/occludin phosphorylation and HCV entry, single lab\",\n      \"pmids\": [\"29538454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TROP2 promotes glioblastoma cell proliferation and metastasis by activating the JAK2/STAT3 signaling pathway; knockdown of TROP2 reduced JAK2 and STAT3 phosphorylation and decreased STAT3 target gene transcription, while JAK2/STAT3 inhibitor WP1066 negated TROP2 overexpression effects, and exogenous IL-6 rescued JAK2/STAT3 phosphorylation in TROP2-silenced cells.\",\n      \"method\": \"siRNA knockdown, overexpression, MTT/BrdU proliferation assays, Transwell migration, western blot for phospho-JAK2/STAT3, pharmacological inhibition with WP1066, IL-6 rescue experiment\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via pharmacological inhibition and rescue experiment places TROP2 upstream of JAK2/STAT3, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30431125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TROP2 promotes osteosarcoma cell proliferation and migration via activation of the PI3K/AKT signaling pathway; overexpression of TROP2 significantly activated PI3K/AKT, while knockdown decreased cell growth and migration.\",\n      \"method\": \"Overexpression and knockdown in osteosarcoma cell lines, proliferation and migration assays, western blot for PI3K/AKT pathway components\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single set of methods, no upstream/downstream pathway validation beyond correlation\",\n      \"pmids\": [\"29845216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Matriptase cleaves TROP2 in vitro when purified recombinant proteins are mixed, and TROP2 is cleaved in 293T cells upon co-transfection with matriptase but not with protease-disabled matriptase or the G827R ichthyosis mutant; in keratinocytes (HaCaT cells), siRNA knockdown of HAI-1 (but not HAI-2 alone) promotes endogenous TROP2 cleavage, and combined EpCAM+TROP2 knockdown markedly reduces claudin-1 and claudin-7 levels (partly reversed by chloroquine), establishing TROP2 and EpCAM as redundant regulators of claudin stability downstream of HAI/matriptase.\",\n      \"method\": \"In vitro reconstitution with purified proteins, co-transfection of 293T cells, siRNA knockdown in HaCaT keratinocytes, western blotting for cleaved TROP2/EpCAM fragments, claudin levels, lysosomal inhibitor (chloroquine) treatment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified proteins confirmed cleavage, complemented by cell-based co-transfection with active-site mutant controls and siRNA epistasis, multiple orthogonal methods in one study\",\n      \"pmids\": [\"32326212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Trop2 promotes intracellular calcium ion release in OSCC cells, drives cell cycle progression to S phase, and inhibits P16 expression through the AMPK pathway; Trop2-mediated Ca2+ release was mechanistically linked to AMPK-dependent suppression of P16.\",\n      \"method\": \"Calcium ion release assays, cell cycle analysis, P16 overexpression rescue, western blot for AMPK pathway, knockdown/overexpression in OSCC cell lines\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, limited mechanistic depth for AMPK-P16 link, P16 overexpression could not rescue Trop2 effects\",\n      \"pmids\": [\"32768481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Trop-2 undergoes proteolytic cleavage in the first thyroglobulin domain loop between residues R87 and T88 by ADAM10; coimmunoprecipitation and mass spectrometry revealed physical interaction of ADAM10 with Trop-2; ADAM10 inhibitors, siRNAs, and shRNAs abolished Trop-2 processing; the R87A-T88A mutant abolished xenograft metastatic dissemination, and the cleavage activates cancer growth and metastasis.\",\n      \"method\": \"Antibody targeting and N-terminal Edman degradation (cleavage site identification), molecular modeling, coimmunoprecipitation + mass spectrometry, immunofluorescence/confocal time-lapse, ADAM10 inhibitors, siRNA/shRNA knockdown, site-directed mutagenesis (R87A-T88A), xenograft metastasis model\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cleavage site identified by Edman degradation, effector protease identified by Co-IP+MS and multiple genetic/pharmacological approaches, functional validation with site mutant in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"33839455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EPCAM and TROP2 share redundant roles in stabilizing claudin-7 at cell membranes and supporting epithelial development; TROP2 deficiency in mice compounded EPCAM-deficiency phenotypes (reduced embryonic viability, shortened postnatal lifespan, loss of claudin-7 membrane localization), and TROP2 could compensate for EPCAM loss in claudin-7 stabilization in tissues co-expressing both proteins.\",\n      \"method\": \"EPCAM and TROP2 knockout mouse models, histology/immunofluorescence, claudin-7 protein localization and expression analysis in multiple tissues\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in double-knockout mouse model with defined molecular phenotype (claudin-7 stabilization), replicated across multiple tissue types\",\n      \"pmids\": [\"35730316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TROP2 translation is enhanced by dual RNA modifications: METTL3-mediated m6A methylation of TROP2 mRNA promotes its translation, and METTL1-mediated m7G modification of specific tRNAs further enhances TROP2 protein production; METTL3/METTL1 double knockout inhibited bladder cancer proliferation/invasion, and TROP2 overexpression partially rescued this phenotype.\",\n      \"method\": \"m6A/m7G methylation assays, METTL3/METTL1 knockout (CRISPR), TROP2 overexpression rescue, in vitro and in vivo proliferation/invasion assays, RNA immunoprecipitation\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual epistasis with rescue experiment, mechanistic link established between two RNA modifications and TROP2 protein level, single lab\",\n      \"pmids\": [\"37268280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Trop2 promotes breast cancer metastasis through a Trop2/β-catenin positive feedback loop; Trop2 physically complexes with β-catenin (identified by immunoprecipitation and mass spectrometry), preventing β-catenin ubiquitin-proteasome degradation and enabling nuclear translocation to transcribe Trop2. Bruceine D binds Trop2 at Lys307 and Glu310 (validated by cellular thermal shift assay and point mutation analyses), disrupts the complex, destabilizes β-catenin, and inhibits EMT and ECM remodeling.\",\n      \"method\": \"Cell membrane chromatography screening, cellular thermal shift assay, point mutation analysis (Lys307/Glu310), immunoprecipitation + mass spectrometry, immunofluorescence, western blot, orthotopic metastasis model\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding site validated by mutagenesis + CETSA, Co-IP+MS for complex, in vivo metastasis model, single lab\",\n      \"pmids\": [\"37271476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TROP2 physically interacts with DSG2 (desmoglein-2) in gastric cancer cells (identified by co-immunoprecipitation and mass spectrometry); TROP2 overexpression reduces DSG2 levels and desmosome assembly, increasing cell invasion and migration via EGFR/AKT and DSG2/plakoglobin/β-catenin pathways.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, TROP2 overexpression and knockdown, electron microscopy for desmosome assembly, western blot for EGFR/AKT and DSG2/PG/β-catenin pathway proteins, adhesion and invasion assays\",\n      \"journal\": \"Current cancer drug targets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP+MS for interaction, functional gain/loss-of-function with pathway readout, single lab\",\n      \"pmids\": [\"35392784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The TACSTD2/M1S1 C108R missense mutation causes the protein to be distributed diffusely in the cytoplasm rather than accumulating at cell-to-cell adhesion borders (as normal TACSTD2 does), demonstrating that the transmembrane/cytoplasmic domain is required for proper membrane localization.\",\n      \"method\": \"Expression vectors for normal and C108R-mutant M1S1 transfected into CHO cells, immunofluorescence localization\",\n      \"journal\": \"Japanese journal of ophthalmology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment in transfected cells comparing wild-type vs. disease mutant, single lab\",\n      \"pmids\": [\"15295654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A GDLD patient-derived conjunctival epithelial cell line lacking functional TACSTD2 has significantly reduced tight junction protein expression and markedly lower transepithelial resistance compared to normal conjunctival epithelial cells, establishing TACSTD2 as necessary for epithelial barrier function.\",\n      \"method\": \"Immortalized patient cell line (lentiviral SV40T/hTERT), protein expression analysis of tight junction proteins, transepithelial resistance (TER) measurements\",\n      \"journal\": \"Transactions of the American Ophthalmological Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional loss-of-function cell line with TER as defined physiological readout, single lab\",\n      \"pmids\": [\"23818740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TACSTD2 promotes platinum resistance in high-grade serous ovarian cancer via the Rap1/PI3K/AKT pathway; RNA-seq analysis of a TACSTD2-representative cisplatin-resistant epithelial subcluster (E0) identified this pathway as the mechanistic basis.\",\n      \"method\": \"Single-cell RNA sequencing, spatial transcriptomics, RNA-seq pathway analysis, TACSTD2 functional analysis in cell lines\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement based primarily on transcriptomic analysis with limited direct functional validation of the specific pathway\",\n      \"pmids\": [\"38817863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TACSTD2 expression in breast cancer cells is regulated by transcription factor EB (TFEB): tamoxifen induces TFEB dephosphorylation (active form), and active TFEB drives TACSTD2 transcription through a tandem E-box motif in the Trop2 promoter; TFEB depletion prevented tamoxifen-induced Trop2 upregulation.\",\n      \"method\": \"TFEB knockdown, luciferase reporter assay with Trop2 promoter E-box motif, western blotting for phospho-TFEB, kinase inhibitor panel, RT-qPCR/western blot for Trop2\",\n      \"journal\": \"Breast cancer (Tokyo, Japan)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with defined promoter element plus siRNA epistasis identifies TFEB as transcriptional activator, single lab\",\n      \"pmids\": [\"35882754\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TACSTD2/TROP2 is a type I transmembrane glycoprotein that transduces intracellular calcium signals and is phosphorylated on Ser303 by protein kinase C; it is proteolytically activated by ADAM10 cleavage (at R87-T88) and by γ-secretase/TACE (releasing the intracellular domain whose nuclear accumulation is amplified by cyclin D1 downstream of Src), cleaved by matriptase (regulated by HAI inhibitors), and physically interacts with claudins, CLDN1/OCLN (regulating their membrane localization and tight junction barrier function), DSG2 (modulating desmosome assembly and EGFR/AKT signaling), and β-catenin (preventing its proteasomal degradation to form a positive feedback loop driving EMT); it signals through ERK MAPK, PI3K/AKT, JAK2/STAT3, and AMPK pathways to promote proliferation, cell cycle progression, survival, invasion, and metastasis, while its expression is transcriptionally regulated by miR-125b-1 and TFEB (via a promoter E-box motif) and translationally enhanced by METTL3/METTL1-mediated dual m6A/m7G RNA modifications.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TACSTD2 (TROP2) is a type I transmembrane glycoprotein that functions both as an epithelial cell-surface signal transducer and as a regulator of intercellular junction integrity, with prominent roles in carcinoma proliferation, survival, and metastasis [#1, #11]. At the membrane it physically partners with tight-junction proteins claudin-1 and occludin and controls their localization and phosphorylation, and acts redundantly with EpCAM to stabilize claudin-7 at cell membranes during epithelial development, such that loss of TACSTD2 disrupts barrier function [#5, #8, #11]. Its activity is gated by sequential proteolysis: ADAM10 cleaves TROP2 within the first thyroglobulin-domain loop between R87 and T88 to drive metastatic dissemination, matriptase (restrained by the HAI-1 inhibitor) cleaves it in keratinocytes, and Src-induced cyclin D1 amplifies γ-secretase/TACE-mediated release of a TROP2 intracellular domain that accumulates in the nucleus to promote cancer stem-cell self-renewal [#10, #8, #4]. The cytoplasmic tail is phosphorylated on Ser303 by protein kinase C, and TROP2 raises intracellular calcium and signals through ERK MAPK, PI3K/AKT, and JAK2/STAT3 cascades to upregulate cyclins D1/E, suppress p27 and p16, and drive cell-cycle progression, invasion, and apoptosis resistance [#0, #1, #6, #7, #9]. TROP2 also complexes with β-catenin to block its proteasomal degradation, forming a positive feedback loop that sustains TROP2 transcription and EMT, and engages DSG2 to remodel desmosomes via EGFR/AKT signaling [#13, #14]. TROP2 abundance is set by miR-125b-1 silencing, TFEB-driven transcription through a promoter E-box, and METTL3/METTL1 dual m6A/m7G RNA modification of its mRNA and tRNAs [#2, #18, #12]. Mutations in TACSTD2 that mislocalize the protein and abolish epithelial barrier function underlie gelatinous drop-like corneal dystrophy [#15, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that the TROP2 cytoplasmic tail is a substrate for intracellular signaling kinases, providing the first evidence that this surface glycoprotein transduces signals rather than acting purely structurally.\",\n      \"evidence\": \"In vitro PKC/PKA kinase assays with phosphopeptide mapping and in vivo 32P-labeling in ME180 cells\",\n      \"pmids\": [\"7635574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream consequences of Ser303 phosphorylation not defined\", \"No link to a specific signaling cascade established at this stage\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linked TACSTD2 to corneal dystrophy mechanistically by showing a disease mutation mislocalizes the protein away from cell-cell borders, implicating the transmembrane/cytoplasmic domain in proper membrane targeting.\",\n      \"evidence\": \"Immunofluorescence of wild-type vs C108R-mutant M1S1 in transfected CHO cells\",\n      \"pmids\": [\"15295654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single ectopic expression system\", \"Functional consequence for junctions not measured in this study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the first concrete pro-tumorigenic signaling output of TROP2 by placing it upstream of ERK-driven cell-cycle progression.\",\n      \"evidence\": \"Gain/loss-of-function in pancreatic cancer cell lines with phospho-ERK/cyclin western blots and in vivo metastasis models\",\n      \"pmids\": [\"20858281\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting surface TROP2 to ERK activation unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified an upstream regulatory layer controlling TROP2 levels, showing miR-125b-1 loss derepresses TACSTD2 to drive MAPK dysfunction in HNSCC.\",\n      \"evidence\": \"miRNA profiling, luciferase reporter validation, and methylation analysis in cell lines and clinical samples\",\n      \"pmids\": [\"23416980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Other regulators of TACSTD2 expression not addressed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected TROP2 to chemoresistance by showing it sustains TAp63-dependent apoptotic gene programs, framing TROP2 loss as a route to apoptosis evasion.\",\n      \"evidence\": \"siRNA knockdown in SCC lines with drug-induced apoptosis assays and TAp63 western blots\",\n      \"pmids\": [\"24651436\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between TROP2 and TAp63 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved how oncogenic Src triggers TROP2 intracellular-domain signaling, identifying cyclin D1 as the transducer that promotes γ-secretase cleavage and nuclear ICD accumulation driving stem-cell self-renewal.\",\n      \"evidence\": \"v-Src transformation of prostate epithelial cells, prostatosphere assays, cyclin D1 epistasis, and ICD immunofluorescence\",\n      \"pmids\": [\"27634768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear targets of the TROP2 ICD not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated TROP2 governs tight-junction protein localization, showing it controls CLDN1/OCLN membrane distribution via phosphorylation and is required for HCV entry.\",\n      \"evidence\": \"siRNA silencing in hepatoma lines and primary hepatocytes with CLDN1/OCLN immunofluorescence and HCV infection assays\",\n      \"pmids\": [\"29538454\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase responsible for claudin/occludin phosphorylation not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended TROP2 signaling to the JAK2/STAT3 axis through pharmacological and cytokine rescue epistasis in glioblastoma.\",\n      \"evidence\": \"Knockdown/overexpression with WP1066 inhibition and IL-6 rescue, phospho-JAK2/STAT3 western blots\",\n      \"pmids\": [\"30431125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical coupling of TROP2 to JAK2 unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Associated TROP2 with PI3K/AKT activation in osteosarcoma proliferation and migration.\",\n      \"evidence\": \"Overexpression/knockdown in osteosarcoma lines with PI3K/AKT western blots and proliferation/migration assays\",\n      \"pmids\": [\"29845216\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No upstream/downstream pathway validation beyond correlation\", \"Single lab, single method set\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established matriptase as a TROP2 protease and positioned TROP2 with EpCAM as redundant HAI/matriptase-regulated stabilizers of claudins.\",\n      \"evidence\": \"In vitro reconstitution with purified proteins, 293T co-transfection with active-site/mutant controls, and HAI-1 siRNA epistasis in keratinocytes\",\n      \"pmids\": [\"32326212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological setting of matriptase cleavage in vivo not established\", \"Cleavage site within TROP2 not mapped here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked TROP2-driven calcium release to AMPK-dependent p16 suppression and S-phase entry in OSCC.\",\n      \"evidence\": \"Calcium release assays, cell cycle analysis, P16 rescue, and AMPK western blots in OSCC lines\",\n      \"pmids\": [\"32768481\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"P16 overexpression could not rescue TROP2 effects, weakening the causal chain\", \"AMPK-P16 mechanism shallow\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified the principal activating protease and cleavage site, showing ADAM10 cuts TROP2 between R87-T88 and that an uncleavable mutant abolishes metastatic dissemination.\",\n      \"evidence\": \"Edman degradation site mapping, Co-IP+MS, ADAM10 inhibitor/siRNA/shRNA, R87A-T88A mutagenesis, and xenograft metastasis model\",\n      \"pmids\": [\"33839455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling events downstream of cleavage incompletely defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided in vivo genetic confirmation that TROP2 and EpCAM are functionally redundant in stabilizing claudin-7 and supporting epithelial development.\",\n      \"evidence\": \"EPCAM/TROP2 single and double knockout mouse models with claudin-7 localization analysis across tissues\",\n      \"pmids\": [\"35730316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of claudin-7 stabilization not resolved\", \"Tissue-specific contributions not fully dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified DSG2 as a TROP2 physical partner and a route by which TROP2 destabilizes desmosomes to drive invasion via EGFR/AKT signaling.\",\n      \"evidence\": \"Co-IP+MS, gain/loss-of-function, electron microscopy of desmosomes, and pathway western blots in gastric cancer cells\",\n      \"pmids\": [\"35392784\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interface not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined TFEB as a transcriptional activator of TACSTD2, showing tamoxifen-induced active TFEB drives Trop2 expression through a promoter E-box.\",\n      \"evidence\": \"TFEB knockdown, Trop2 promoter E-box luciferase reporter, and phospho-TFEB western blots in breast cancer cells\",\n      \"pmids\": [\"35882754\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Broader signaling context of TFEB-TROP2 axis not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed post-transcriptional control of TROP2 protein output through dual m6A/m7G RNA modifications.\",\n      \"evidence\": \"METTL3/METTL1 CRISPR knockout, m6A/m7G assays, RNA-IP, and TROP2 overexpression rescue in bladder cancer\",\n      \"pmids\": [\"37268280\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of m6A vs m7G to TROP2 levels not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered a TROP2/β-catenin positive feedback loop that stabilizes β-catenin and sustains TROP2 transcription to drive EMT and metastasis.\",\n      \"evidence\": \"Co-IP+MS, CETSA and Lys307/Glu310 mutagenesis with the inhibitor Bruceine D, and orthotopic metastasis model\",\n      \"pmids\": [\"37271476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which TROP2 blocks β-catenin ubiquitination not detailed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Associated TACSTD2 with platinum resistance in ovarian cancer via the Rap1/PI3K/AKT pathway.\",\n      \"evidence\": \"Single-cell RNA-seq, spatial transcriptomics, and pathway analysis with functional analysis in cell lines\",\n      \"pmids\": [\"38817863\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pathway placement rests largely on transcriptomics\", \"Limited direct functional validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple TROP2 proteolytic events, junctional interactions, and intracellular signaling cascades are integrated into a single coherent regulatory program — and which kinase mediates TROP2-dependent claudin/occludin phosphorylation — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking ICD nuclear signaling to surface junction regulation\", \"Kinase for claudin/occludin phosphorylation unidentified\", \"Structural basis of partner interactions not solved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 6, 9]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [5, 11, 16]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 8, 11, 15]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 7]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 10]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [5, 11, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CLDN1\", \"OCLN\", \"CLDN7\", \"EPCAM\", \"DSG2\", \"CTNNB1\", \"ADAM10\", \"MST1R\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}